APO Research
Talk to an analyst

APO RESEARCH · REPORT

Formulation Development CDMO

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Formulation Development CDMO Market Outlook and Growth Opportunities 2026

5 June 2026213 pages

Choose your research edition.

Industry ResearchFormulation Development CDMO Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Formulation Development CDMO Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Formulation Development CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Formulation Development CDMO Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Formulation Development CDMO Market Analysis and Forecast 2026-2032242 pages · $4,950 USD

Market perspective

The global Formulation Development CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Formulation Development CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Formulation Development CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Formulation Development CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Formulation Development CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Formulation Development CDMO market include Lonza, Ascendia Pharmaceutical Solutions, Catalent, Cambrex, Serán Bioscience, Singota Solutions, Adragos Pharma, Meribel Pharma and Eurofins CDMO, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Formulation Development CDMO market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Formulation Development CDMO and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Formulation Development CDMO revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Formulation Development CDMO market.

Formulation Development CDMO Segment by Company

Lonza

Ascendia Pharmaceutical Solutions

Catalent

Cambrex

Serán Bioscience

Singota Solutions

Adragos Pharma

Meribel Pharma

Eurofins CDMO

Skyepharma

Siegfried Group

Recipharm

CordenPharma

Thermo Fisher Scientific

Samsung Biologics

AGC Biologics

WuXi AppTec

Pharmaron

Asymchem

Huahai Pharma

Nipro Pharma

CMIC Group

Hovione

Formulation Development CDMO Segment by Type

Oral Solid Dosage Forms

Injectable Dosage Forms

Transdermal Dosage Forms

Others

Formulation Development CDMO Segment by Application

Small molecule chemical drugs

Biologics

Cell and gene therapy products

Others

Formulation Development CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Formulation Development CDMO status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Formulation Development CDMO key companies, revenue, market share, and recent developments.

3. To split the Formulation Development CDMO breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Formulation Development CDMO market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Formulation Development CDMO significant trends, drivers, influence factors in global and regions.

6. To analyze Formulation Development CDMO competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Formulation Development CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Formulation Development CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Formulation Development CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Formulation Development CDMO industry.

Chapter 3: Detailed analysis of Formulation Development CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Formulation Development CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Formulation Development CDMO in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Formulation Development CDMO Industry Trends Table 2. Formulation Development CDMO Industry Drivers Table 3. Formulation Development CDMO Industry Opportunities and Challenges Table 4. Formulation Development CDMO Industry Restraints Table 5. Global Formulation Development CDMO Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Formulation Development CDMO Revenue Share by Company (2021-2026) Table 7. Global Formulation Development CDMO Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Formulation Development CDMO Key Company Manufacturing Base & Headquarters Table 9. Global Formulation Development CDMO Company, Product Type & Application Table 10. Global Formulation Development CDMO Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Formulation Development CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Oral Solid Dosage Forms Table 15. Significant Companies of Injectable Dosage Forms Table 16. Significant Companies of Transdermal Dosage Forms Table 17. Significant Companies of Others Table 18. Global Formulation Development CDMO Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Formulation Development CDMO Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Formulation Development CDMO Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Formulation Development CDMO Sales Value Share by Type (2021-2026) Table 22. Global Formulation Development CDMO Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Small molecule chemical drugs Table 24. Significant Companies of Biologics Table 25. Significant Companies of Cell and gene therapy products Table 26. Significant Companies of Others Table 27. Global Formulation Development CDMO Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Formulation Development CDMO Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Formulation Development CDMO Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Formulation Development CDMO Sales Value Share by Application (2021-2026) Table 31. Global Formulation Development CDMO Sales Value Share by Application (2027-2032) Table 32. Global Formulation Development CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Formulation Development CDMO Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Formulation Development CDMO Sales Value Share by Region (2021-2026) Table 35. Global Formulation Development CDMO Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Formulation Development CDMO Sales Value Share by Region (2027-2032) Table 37. Global Formulation Development CDMO Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Formulation Development CDMO Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Formulation Development CDMO Sales Value Market Share by Country (2021-2026) Table 40. Global Formulation Development CDMO Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Formulation Development CDMO Sales Value Market Share by Country (2027-2032) Table 42. Lonza Company Information Table 43. Lonza Business Overview Table 44. Lonza Formulation Development CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Lonza Formulation Development CDMO Product Portfolio Table 46. Lonza Recent Development Table 47. Ascendia Pharmaceutical Solutions Company Information Table 48. Ascendia Pharmaceutical Solutions Business Overview Table 49. Ascendia Pharmaceutical Solutions Formulation Development CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Ascendia Pharmaceutical Solutions Formulation Development CDMO Product Portfolio Table 51. Ascendia Pharmaceutical Solutions Recent Development Table 52. Catalent Company Information Table 53. Catalent Business Overview Table 54. Catalent Formulation Development CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Catalent Formulation Development CDMO Product Portfolio Table 56. Catalent Recent Development Table 57. Cambrex Company Information Table 58. Cambrex Business Overview Table 59. Cambrex Formulation Development CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Cambrex Formulation Development CDMO Product Portfolio Table 61. Cambrex Recent Development Table 62. Serán Bioscience Company Information Table 63. Serán Bioscience Business Overview Table 64. Serán Bioscience Formulation Development CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Serán Bioscience Formulation Development CDMO Product Portfolio Table 66. Serán Bioscience Recent Development Table 67. Singota Solutions Company Information Table 68. Singota Solutions Business Overview Table 69. Singota Solutions Formulation Development CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Singota Solutions Formulation Development CDMO Product Portfolio Table 71. Singota Solutions Recent Development Table 72. Adragos Pharma Company Information Table 73. Adragos Pharma Business Overview Table 74. Adragos Pharma Formulation Development CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Adragos Pharma Formulation Development CDMO Product Portfolio Table 76. Adragos Pharma Recent Development Table 77. Meribel Pharma Company Information Table 78. Meribel Pharma Business Overview Table 79. Meribel Pharma Formulation Development CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Meribel Pharma Formulation Development CDMO Product Portfolio Table 81. Meribel Pharma Recent Development Table 82. Eurofins CDMO Company Information Table 83. Eurofins CDMO Business Overview Table 84. Eurofins CDMO Formulation Development CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Eurofins CDMO Formulation Development CDMO Product Portfolio Table 86. Eurofins CDMO Recent Development Table 87. Skyepharma Company Information Table 88. Skyepharma Business Overview Table 89. Skyepharma Formulation Development CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Skyepharma Formulation Development CDMO Product Portfolio Table 91. Skyepharma Recent Development Table 92. Siegfried Group Company Information Table 93. Siegfried Group Business Overview Table 94. Siegfried Group Formulation Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. Siegfried Group Formulation Development CDMO Product Portfolio Table 96. Siegfried Group Recent Development Table 97. Recipharm Company Information Table 98. Recipharm Business Overview Table 99. Recipharm Formulation Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. Recipharm Formulation Development CDMO Product Portfolio Table 101. Recipharm Recent Development Table 102. CordenPharma Company Information Table 103. CordenPharma Business Overview Table 104. CordenPharma Formulation Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. CordenPharma Formulation Development CDMO Product Portfolio Table 106. CordenPharma Recent Development Table 107. Thermo Fisher Scientific Company Information Table 108. Thermo Fisher Scientific Business Overview Table 109. Thermo Fisher Scientific Formulation Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 110. Thermo Fisher Scientific Formulation Development CDMO Product Portfolio Table 111. Thermo Fisher Scientific Recent Development Table 112. Samsung Biologics Company Information Table 113. Samsung Biologics Business Overview Table 114. Samsung Biologics Formulation Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 115. Samsung Biologics Formulation Development CDMO Product Portfolio Table 116. Samsung Biologics Recent Development Table 117. AGC Biologics Company Information Table 118. AGC Biologics Business Overview Table 119. AGC Biologics Formulation Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 120. AGC Biologics Formulation Development CDMO Product Portfolio Table 121. AGC Biologics Recent Development Table 122. WuXi AppTec Company Information Table 123. WuXi AppTec Business Overview Table 124. WuXi AppTec Formulation Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 125. WuXi AppTec Formulation Development CDMO Product Portfolio Table 126. WuXi AppTec Recent Development Table 127. Pharmaron Company Information Table 128. Pharmaron Business Overview Table 129. Pharmaron Formulation Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 130. Pharmaron Formulation Development CDMO Product Portfolio Table 131. Pharmaron Recent Development Table 132. Asymchem Company Information Table 133. Asymchem Business Overview Table 134. Asymchem Formulation Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 135. Asymchem Formulation Development CDMO Product Portfolio Table 136. Asymchem Recent Development Table 137. Huahai Pharma Company Information Table 138. Huahai Pharma Business Overview Table 139. Huahai Pharma Formulation Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 140. Huahai Pharma Formulation Development CDMO Product Portfolio Table 141. Huahai Pharma Recent Development Table 142. Nipro Pharma Company Information Table 143. Nipro Pharma Business Overview Table 144. Nipro Pharma Formulation Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 145. Nipro Pharma Formulation Development CDMO Product Portfolio Table 146. Nipro Pharma Recent Development Table 147. CMIC Group Company Information Table 148. CMIC Group Business Overview Table 149. CMIC Group Formulation Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 150. CMIC Group Formulation Development CDMO Product Portfolio Table 151. CMIC Group Recent Development Table 152. Hovione Company Information Table 153. Hovione Business Overview Table 154. Hovione Formulation Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 155. Hovione Formulation Development CDMO Product Portfolio Table 156. Hovione Recent Development Table 157. Research Programs/Design for This Report Table 158. Authors List of This Report Table 159. Secondary Sources Table 160. Primary Sources List of Figures Figure 1. Formulation Development CDMO Product Image Figure 2. Global Formulation Development CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 4. Global Formulation Development CDMO Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Oral Solid Dosage Forms Image Figure 8. Injectable Dosage Forms Image Figure 9. Transdermal Dosage Forms Image Figure 10. Others Image Figure 11. Global Formulation Development CDMO Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Formulation Development CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Formulation Development CDMO Sales Value Share by Type (2021-2032) Figure 14. Small molecule chemical drugs Image Figure 15. Biologics Image Figure 16. Cell and gene therapy products Image Figure 17. Others Image Figure 18. Global Formulation Development CDMO Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Formulation Development CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Formulation Development CDMO Sales Value Share by Application (2021-2032) Figure 21. Global Formulation Development CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Formulation Development CDMO Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Formulation Development CDMO Sales Value (2021-2032) & (US$ Million) Figure 24. North America Formulation Development CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Formulation Development CDMO Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Formulation Development CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Formulation Development CDMO Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Formulation Development CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Formulation Development CDMO Sales Value (2021-2032) & (US$ Million) Figure 30. South America Formulation Development CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Formulation Development CDMO Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Formulation Development CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Formulation Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Solid Dosage Forms
  • Injectable Dosage Forms
  • Transdermal Dosage Forms
  • Others
Applications
  • Small molecule chemical drugs
  • Biologics
  • Cell and gene therapy products
  • Others
Companies covered
  • Lonza
  • Ascendia Pharmaceutical Solutions
  • Catalent
  • Cambrex
  • Serán Bioscience
  • Singota Solutions
  • Adragos Pharma
  • Meribel Pharma
  • Eurofins CDMO
  • Skyepharma
  • Siegfried Group
  • Recipharm
  • CordenPharma
  • Thermo Fisher Scientific
  • Samsung Biologics
  • AGC Biologics
  • WuXi AppTec
  • Pharmaron
  • Asymchem
  • Huahai Pharma
  • Nipro Pharma
  • CMIC Group
  • Hovione

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Formulation Development CDMO Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Formulation Development CDMO Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Formulation Development CDMO Market Dynamics
  1. 2.1 Formulation Development CDMO Industry Trends
  2. 2.2 Formulation Development CDMO Industry Drivers
  3. 2.3 Formulation Development CDMO Industry Opportunities and Challenges
  4. 2.4 Formulation Development CDMO Industry Restraints
3 Formulation Development CDMO Market by Company
  1. 3.1 Global Formulation Development CDMO Company Revenue Ranking in 2025
  2. 3.2 Global Formulation Development CDMO Revenue by Company (2021-2026)
  3. 3.3 Global Formulation Development CDMO Company Ranking (2024-2026)
  4. 3.4 Global Formulation Development CDMO Company Manufacturing Base and Headquarters
  5. 3.5 Global Formulation Development CDMO Company Product Type and Application
  6. 3.6 Global Formulation Development CDMO Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Formulation Development CDMO Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Formulation Development CDMO Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Formulation Development CDMO Market by Type
  1. 4.1 Formulation Development CDMO Type Introduction
  2. 4.1.1 Oral Solid Dosage Forms
  3. 4.1.2 Injectable Dosage Forms
  4. 4.1.3 Transdermal Dosage Forms
  5. 4.1.4 Others
  6. 4.2 Global Formulation Development CDMO Sales Value by Type
  7. 4.2.1 Global Formulation Development CDMO Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Formulation Development CDMO Sales Value by Type (2021-2032)
  9. 4.2.3 Global Formulation Development CDMO Sales Value Share by Type (2021-2032)
5 Formulation Development CDMO Market by Application
  1. 5.1 Formulation Development CDMO Application Introduction
  2. 5.1.1 Small molecule chemical drugs
  3. 5.1.2 Biologics
  4. 5.1.3 Cell and gene therapy products
  5. 5.1.4 Others
  6. 5.2 Global Formulation Development CDMO Sales Value by Application
  7. 5.2.1 Global Formulation Development CDMO Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Formulation Development CDMO Sales Value by Application (2021-2032)
  9. 5.2.3 Global Formulation Development CDMO Sales Value Share by Application (2021-2032)
6 Formulation Development CDMO Regional Value Analysis
  1. 6.1 Global Formulation Development CDMO Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Formulation Development CDMO Sales Value by Region (2021-2032)
  3. 6.2.1 Global Formulation Development CDMO Sales Value by Region: 2021-2026
  4. 6.2.2 Global Formulation Development CDMO Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Formulation Development CDMO Sales Value (2021-2032)
  7. 6.3.2 North America Formulation Development CDMO Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Formulation Development CDMO Sales Value (2021-2032)
  10. 6.4.2 Europe Formulation Development CDMO Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Formulation Development CDMO Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Formulation Development CDMO Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Formulation Development CDMO Sales Value (2021-2032)
  16. 6.6.2 South America Formulation Development CDMO Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Formulation Development CDMO Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Formulation Development CDMO Sales Value Share by Country, 2025 VS 2032
7 Formulation Development CDMO Country-level Value Analysis
  1. 7.1 Global Formulation Development CDMO Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Formulation Development CDMO Sales Value by Country (2021-2032)
  3. 7.2.1 Global Formulation Development CDMO Sales Value by Country (2021-2026)
  4. 7.2.2 Global Formulation Development CDMO Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Formulation Development CDMO Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Formulation Development CDMO Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Formulation Development CDMO Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Lonza
  2. 8.1.1 Lonza Company Information
  3. 8.1.2 Lonza Business Overview
  4. 8.1.3 Lonza Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Lonza Formulation Development CDMO Product Portfolio
  6. 8.1.5 Lonza Recent Developments
  7. 8.2 Ascendia Pharmaceutical Solutions
  8. 8.2.1 Ascendia Pharmaceutical Solutions Company Information
  9. 8.2.2 Ascendia Pharmaceutical Solutions Business Overview
  10. 8.2.3 Ascendia Pharmaceutical Solutions Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Ascendia Pharmaceutical Solutions Formulation Development CDMO Product Portfolio
  12. 8.2.5 Ascendia Pharmaceutical Solutions Recent Developments
  13. 8.3 Catalent
  14. 8.3.1 Catalent Company Information
  15. 8.3.2 Catalent Business Overview
  16. 8.3.3 Catalent Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Catalent Formulation Development CDMO Product Portfolio
  18. 8.3.5 Catalent Recent Developments
  19. 8.4 Cambrex
  20. 8.4.1 Cambrex Company Information
  21. 8.4.2 Cambrex Business Overview
  22. 8.4.3 Cambrex Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Cambrex Formulation Development CDMO Product Portfolio
  24. 8.4.5 Cambrex Recent Developments
  25. 8.5 Serán Bioscience
  26. 8.5.1 Serán Bioscience Company Information
  27. 8.5.2 Serán Bioscience Business Overview
  28. 8.5.3 Serán Bioscience Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Serán Bioscience Formulation Development CDMO Product Portfolio
  30. 8.5.5 Serán Bioscience Recent Developments
  31. 8.6 Singota Solutions
  32. 8.6.1 Singota Solutions Company Information
  33. 8.6.2 Singota Solutions Business Overview
  34. 8.6.3 Singota Solutions Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Singota Solutions Formulation Development CDMO Product Portfolio
  36. 8.6.5 Singota Solutions Recent Developments
  37. 8.7 Adragos Pharma
  38. 8.7.1 Adragos Pharma Company Information
  39. 8.7.2 Adragos Pharma Business Overview
  40. 8.7.3 Adragos Pharma Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Adragos Pharma Formulation Development CDMO Product Portfolio
  42. 8.7.5 Adragos Pharma Recent Developments
  43. 8.8 Meribel Pharma
  44. 8.8.1 Meribel Pharma Company Information
  45. 8.8.2 Meribel Pharma Business Overview
  46. 8.8.3 Meribel Pharma Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Meribel Pharma Formulation Development CDMO Product Portfolio
  48. 8.8.5 Meribel Pharma Recent Developments
  49. 8.9 Eurofins CDMO
  50. 8.9.1 Eurofins CDMO Company Information
  51. 8.9.2 Eurofins CDMO Business Overview
  52. 8.9.3 Eurofins CDMO Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Eurofins CDMO Formulation Development CDMO Product Portfolio
  54. 8.9.5 Eurofins CDMO Recent Developments
  55. 8.10 Skyepharma
  56. 8.10.1 Skyepharma Company Information
  57. 8.10.2 Skyepharma Business Overview
  58. 8.10.3 Skyepharma Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Skyepharma Formulation Development CDMO Product Portfolio
  60. 8.10.5 Skyepharma Recent Developments
  61. 8.11 Siegfried Group
  62. 8.11.1 Siegfried Group Company Information
  63. 8.11.2 Siegfried Group Business Overview
  64. 8.11.3 Siegfried Group Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Siegfried Group Formulation Development CDMO Product Portfolio
  66. 8.11.5 Siegfried Group Recent Developments
  67. 8.12 Recipharm
  68. 8.12.1 Recipharm Company Information
  69. 8.12.2 Recipharm Business Overview
  70. 8.12.3 Recipharm Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Recipharm Formulation Development CDMO Product Portfolio
  72. 8.12.5 Recipharm Recent Developments
  73. 8.13 CordenPharma
  74. 8.13.1 CordenPharma Company Information
  75. 8.13.2 CordenPharma Business Overview
  76. 8.13.3 CordenPharma Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  77. 8.13.4 CordenPharma Formulation Development CDMO Product Portfolio
  78. 8.13.5 CordenPharma Recent Developments
  79. 8.14 Thermo Fisher Scientific
  80. 8.14.1 Thermo Fisher Scientific Company Information
  81. 8.14.2 Thermo Fisher Scientific Business Overview
  82. 8.14.3 Thermo Fisher Scientific Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Thermo Fisher Scientific Formulation Development CDMO Product Portfolio
  84. 8.14.5 Thermo Fisher Scientific Recent Developments
  85. 8.15 Samsung Biologics
  86. 8.15.1 Samsung Biologics Company Information
  87. 8.15.2 Samsung Biologics Business Overview
  88. 8.15.3 Samsung Biologics Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Samsung Biologics Formulation Development CDMO Product Portfolio
  90. 8.15.5 Samsung Biologics Recent Developments
  91. 8.16 AGC Biologics
  92. 8.16.1 AGC Biologics Company Information
  93. 8.16.2 AGC Biologics Business Overview
  94. 8.16.3 AGC Biologics Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  95. 8.16.4 AGC Biologics Formulation Development CDMO Product Portfolio
  96. 8.16.5 AGC Biologics Recent Developments
  97. 8.17 WuXi AppTec
  98. 8.17.1 WuXi AppTec Company Information
  99. 8.17.2 WuXi AppTec Business Overview
  100. 8.17.3 WuXi AppTec Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  101. 8.17.4 WuXi AppTec Formulation Development CDMO Product Portfolio
  102. 8.17.5 WuXi AppTec Recent Developments
  103. 8.18 Pharmaron
  104. 8.18.1 Pharmaron Company Information
  105. 8.18.2 Pharmaron Business Overview
  106. 8.18.3 Pharmaron Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Pharmaron Formulation Development CDMO Product Portfolio
  108. 8.18.5 Pharmaron Recent Developments
  109. 8.19 Asymchem
  110. 8.19.1 Asymchem Company Information
  111. 8.19.2 Asymchem Business Overview
  112. 8.19.3 Asymchem Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Asymchem Formulation Development CDMO Product Portfolio
  114. 8.19.5 Asymchem Recent Developments
  115. 8.20 Huahai Pharma
  116. 8.20.1 Huahai Pharma Company Information
  117. 8.20.2 Huahai Pharma Business Overview
  118. 8.20.3 Huahai Pharma Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Huahai Pharma Formulation Development CDMO Product Portfolio
  120. 8.20.5 Huahai Pharma Recent Developments
  121. 8.21 Nipro Pharma
  122. 8.21.1 Nipro Pharma Company Information
  123. 8.21.2 Nipro Pharma Business Overview
  124. 8.21.3 Nipro Pharma Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Nipro Pharma Formulation Development CDMO Product Portfolio
  126. 8.21.5 Nipro Pharma Recent Developments
  127. 8.22 CMIC Group
  128. 8.22.1 CMIC Group Company Information
  129. 8.22.2 CMIC Group Business Overview
  130. 8.22.3 CMIC Group Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  131. 8.22.4 CMIC Group Formulation Development CDMO Product Portfolio
  132. 8.22.5 CMIC Group Recent Developments
  133. 8.23 Hovione
  134. 8.23.1 Hovione Company Information
  135. 8.23.2 Hovione Business Overview
  136. 8.23.3 Hovione Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Hovione Formulation Development CDMO Product Portfolio
  138. 8.23.5 Hovione Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst